(Q33940388)

30 July 2017

1 reference

title

An overview of cancer immunotherapy (English)

1 reference

30 July 2017

1 reference

Davis ID

1

1 reference

30 July 2017

publication date

1 June 2000

1 reference

Immunology & Cell Biology

30 July 2017

published in

1 reference

30 July 2017

volume

78

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

179-195

1 reference

Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Single-cell PCR analysis of TCR repertoires selected by antigen in vivo: a high magnitude CD8 response is comprised of very few clones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Coley's toxins in perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Immunity to methylcholanthrene-induced tumours in inbred rats following atrophy and regression of the implanted tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

SSX: a multigene family with several members transcribed in normal testis and human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Phase II study of vaccinia melanoma cell lysates (VMCL) as adjuvant to surgical treatment of stage II melanoma. II. Effects on cell mediated cytotoxicity and leucocyte dependent antibody activity: immunological effects of VMCL in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (CancerVax): correlation with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Antibody responses to melanoma/melanocyte autoantigens in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Identification of human cancers deficient in antigen processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Cancer gene therapy: connecting basic research with clinical inquiry

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Cancer therapy using a self-replicating RNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

CpG motifs in bacterial DNA trigger direct B-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp 160 envelope proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Cells in stress: transcriptional activation of heat shock genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Role of the major heat shock proteins as molecular chaperones

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Exposure of monocytes to heat shock does not increase class II expression but modulates antigen-dependent T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Molecular chaperones in the processing and presentation of antigen to helper T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4-8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

ATP is required for in vitro assembly of MHC class I antigens but not for transfer of peptides across the ER membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Protective effects of hsp70 in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

A peptide binding protein having a role in antigen presentation is a member of the HSP70 heat shock family

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Heat shock protein 70-associated peptides elicit specific cancer immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Heat shock proteins transfer peptides during antigen processing and CTL priming

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Peptide binding and presentation by mouse CD1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Ceramide inhibits antigen uptake and presentation by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Alternative antigen processing pathways in anti-infective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

CD1 presentation of microbial nonpeptide antigens to T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Carbohydrate/peptide mimics: effect on MUC1 cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Approaching the asymptote? Evolution and revolution in immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Tolerance, danger, and the extended family

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

An endotoxin-induced serum factor that causes necrosis of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Both immunization with protein and recombinant vaccinia virus can stimulate CTL specific for the E7 protein of human papilloma virus 16 in H-2d mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

The use of melanosomal proteins in the immunotherapy of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

ISCOMs (immunostimulating complexes): the first decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

A case report: immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Class I MHC presentation of exogenous antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

In vivo detection of dendritic cell antigen presentation to CD4(+) T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Follow-up evaluation of a phase II prostate cancer vaccine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Antibody-based immunological therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Monoclonal antibody-directed cytotoxic therapy: potential in malignant diseases of aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

New drugs in the treatment of colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Histamine in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Tissue microarrays for high-throughput molecular profiling of tumor specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Microarrays: biotechnology's discovery platform for functional genomics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

DNA chips: state-of-the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

Protein microarrays for gene expression and antibody screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2000.00906.X

10.1046/J.1440-1711.2000.00906.X

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference